<DOC>
	<DOCNO>NCT00417638</DOCNO>
	<brief_summary>Rapid MI-ICE-Pilot design demonstrate safety efficacy Celsius Control™ System ( CCS ) endovascular catheter reduce infarct size result acute anterior myocardial infarction use combination cold saline adjunct immediate percutaneous coronary intervention ( PCI ) patient occlude infarct-related artery .</brief_summary>
	<brief_title>Rapid Intravascular Cooling Myocardial Infarction Adjunctive Percutaneous Coronary Intervention</brief_title>
	<detailed_description>The CCS endovascular thermal control system circulate cooled saline indwell central venous catheter closed-loop manner . The system receive 510 ( k ) approval FDA use temperature management neuro-surgical cardiac patient surgery recovery/intensive care . It also receive European CE mark Australian TGA approval . Animal data model acute myocardial infraction support hypothesis rapid cooling , prior acute PCI , may reduce infarct size . Meta-analysis previous acute MI trial ICE-IT ( N = 228 ; 1:1 randomization , hypothermia : control , Innercool Therapies , Inc. ) COOL MI-I ( Radiant Medical , Inc ) suggest reduction infarct size measure 30-day SPECT population patient anterior MIs cool 35 C prior PCI . This study design investigate safety , feasibility efficacy rapid endovascular cool set acute PCI patient anterior infarction .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Anterior Wall Myocardial Infarction</mesh_term>
	<criteria>Each eligible patient must meet follow inclusion criterion : 1 . Have ECG evidence ongoing acute anterior myocardial infarction , involve large area myocardium , define follow ECG criterion : a. Anterior infarct : STsegment elevation &gt; 0.2mV measure 0.08 sec J point 2 anatomically contiguous precordial lead , V1 V4 ; and/or &gt; 0.2mV lead V5 V6 2 . Present RAPID MIICE site within six ( 6 ) hour onset acute cardiac ischemic sign symptom ( chest pain pressure , arm jaw pain , dyspnea , nausea/vomiting , syncope ) 3 . Be candidate PCI PCI plan immediate intervention . 4 . Be willing able comply study procedure , include return MRI scan 4 ±2 day return clinical examination Day 30 5 . Provide write informed consent prior initiation studyspecific procedures 6 . Be Killips Class I Patients eligible study meet one follow criterion : 1 . Age less eighteen ( &lt; 18 ) year age 2 . Age great seventyfive ( &gt; 75 ) year age 3 . Are pregnant 4 . Have suspect aortic dissection 5 . History prior anterior myocardial infarct prior large myocardial infarct . 6 . The suspected etiology myocardial infarction primarily relate substance abuse ( e.g. , cocaine , methamphetamine , etc . ) 7 . Acute administration thrombolytic agent qualify MI 8 . If ( screen process ) determination make sitestudy personnel initiation cool prior diagnostic coronary angiography technically feasible reason ( patient randomize Hypothermia Arm ) , prospective subject enrol 9 . Require immediate surgical procedural intervention PCI ( e.g . CABG ) 10 . Present cardiogenic shock endstage cardiomyopathy 11 . Have undergone least ten ( 10 ) minute cardiopulmonary resuscitation ( CPR ) prior presentation PCI facility 12 . History previous MI known , preexisting , anterior pathologic Qwaves 13 . History surgical coronary artery revascularization ( e.g. , CABG , MIDCAB , OPCAB ) 14 . Recent stroke ( within 3 month ) 15 . Active bleeding , coagulopathy , contraindication placement heparincoated 14F central venous catheter via 14F femoral venous introducer sheath ( e.g. , known history heparin induce thrombocytopenia , IVC filter ) 16 . Contraindications hypothermia , patient know hematologic dyscrasia affect thrombosis ( e.g. , cryoglobulinemia , sickle cell disease , serum cold agglutinin ) vasospastic disorder ( Raynaud 's thromboangitis obliterans ) 17 . Personal familial history malignant hyperthermia 18 . Known endstage renal disease ( ESRD ; e.g. , dialysis , statuspost renal transplant ) , know hepatic failure ( e.g. , cirrhosis , acute hepatitis ) , contraindication receive meperidine ( use MAO inhibitor within previous 14 day , history seizure , history hypersensitivity meperidine , etc . ) [ Note : Patients contraindication buspirone administration may enrol give buspirone part antishivering regimen . ] 19 . Any acute chronic condition Investigator believe unacceptably increase risk study participation interfere study procedure assessments 20 . Deemed unsuitable investigator participate study . 21 . Signs cardiogenic shock sign significant heart failure rales lung 22 . Active recent ( within 1 month prior study enrollment ) participation another investigational clinical research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>acute intervention</keyword>
	<keyword>percutaneous intervention</keyword>
	<keyword>endovascular cooling</keyword>
	<keyword>endovascular rewarming</keyword>
</DOC>